According to the present invention, a crystal of reduced glutathione having a reduced content of impurities, particularly L-cysteinyl-L-glycine and a method for producing the same are provided. The present invention relates to a crystal of reduced glutathione, wherein, in a high-performance liquid chromatography (HPLC) analysis, the peak area of L-cysteinyl-L-glycine is 0.02 or less with respect to the peak area of reduced glutathione which is taken as 100.

The present invention relates to technical fields of organic chemistry and pharmaceutical chemistry, specifically to water-soluble rapamycin derivatives modified with glutathione. More specifically, the present invention discloses a compound of formula I and the preparation method thereof, wherein R.sub.1 and R.sub.2 are as defined in the description. The compound of formula I can be used in inducing immunosuppression and in the treatment of diseases such as transplant rejection and solid tumor, etc.

##STR00001##

Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from glutathione and a derivative thereof, and the derivative of glutathione is selected from: at least one of amino or carboxyl in glutathione substituted with an amino protecting group and/or a carboxyl protecting group; B is a monovalent or divalent balance anion; and n is 1 or 2.

[M(A).sub.2].Math.nB(I)

Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.

The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, diabetes, degenerative diseases of the eye (ARMD), nephropathy and neuropathy.

The present disclosure relates to a method for manufacturing a metal nanostructure having a chiral structure. The method for manufacturing a metal nanostructure comprises: preparing a first mixture solution by mixing a metal precursor, a surfactant, and a reducing agent; preparing a second mixture solution by adding a peptide to the first mixture solution; and preparing a metal nanostructure having a chiral structure by adding a metal seed particle to the second mixture solution.

A mutant glutamate-cysteine ligase (GSHA) suitable for generating -Glu-Val, and a method for producing -Glu-Val-Gly using the same are provided. -Glu-Val is produced by using a mutant GSHA having a specific mutation with Glu and Val as raw materials, and -Glu-Val-Gly is further produced by using -Glu-Val and Gly as raw materials. -Glu-Val-Gly is produced by using a mutant GSHA having a specific mutation with Glu, Val, and Gly as raw materials.

The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid- peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.

The present invention provides compounds of Formula (I) and (II): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, X and n are as defined herein, and wherein R.sup.3 is hydrogen or a sulfur protecting group. Compounds of Formula (I) and (II), wherein R.sup.3 is hydrogen, may be useful in methods for detecting a reactive metabolite in a sample, e.g., wherein the metabolite is generated from the metabolism of a test compound, and wherein the metabolite and the compound of Formula (I) or (II) react to form a detectable adduct, e.g., detectable by mass spectrometry.

A method of producing reduced glutathione by electrolytic reduction of oxidized glutathione using a cathode cell and an anode cell separated from each other by a separating membrane, including using a cathode having a metal cathode surface, and, as a cathode solution, an aqueous oxidized glutathione solution having a pH adjusted to higher than 3.0 and 5.0 or below by adding a base, which is added with the same metal as the metal of the cathode surface, a metal salt thereof, or a metal oxide thereof.